Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTMDNASDAQ:DSGNNASDAQ:INBXNASDAQ:MGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$4.12+2.5%$3.79$3.04▼$8.44$219.93M1.21175,185 shs97,382 shsDSGNDesign Therapeutics$3.52+4.5%$3.86$2.60▼$7.77$191.31M1.56178,626 shs97,232 shsINBXInhibrx Biosciences$14.67+2.8%$13.21$10.80▼$17.79$206.57M-0.0496,352 shs80,333 shsMGXMetagenomi$1.52+2.4%$1.59$1.23▼$5.50$55.33M-0.38836,570 shs452,787 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote+2.49%+3.26%+18.05%+19.08%-44.32%DSGNDesign Therapeutics+4.45%-11.34%-5.63%-7.12%+8.31%INBXInhibrx Biosciences+2.80%-0.61%+8.19%+4.04%+6.77%MGXMetagenomi+2.36%-1.62%-10.37%+13.91%-65.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBTMDbiote3.3723 of 5 stars3.52.00.00.02.73.31.3DSGNDesign Therapeutics1.3964 of 5 stars2.01.00.00.03.32.50.6INBXInhibrx Biosciences1.5313 of 5 stars0.01.00.04.62.01.71.3MGXMetagenomi2.5408 of 5 stars3.52.00.00.02.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTMDbiote 3.00Buy$8.0094.17% UpsideDSGNDesign Therapeutics 2.00Hold$4.0013.64% UpsideINBXInhibrx Biosciences 2.00HoldN/AN/AMGXMetagenomi 3.00Buy$13.00758.09% UpsideCurrent Analyst Ratings BreakdownLatest MGX, BTMD, INBX, and DSGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025INBXInhibrx BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/15/2025MGXMetagenomiChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$13.00 ➝ $12.005/14/2025MGXMetagenomiWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$20.00 ➝ $16.004/3/2025MGXMetagenomiHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $7.00(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTMDbiote$197.19M1.14$0.78 per share5.25($2.78) per share-1.48DSGNDesign TherapeuticsN/AN/AN/AN/A$4.28 per shareN/AINBXInhibrx Biosciences$200K1,062.11$122.25 per share0.12$9.23 per share1.59MGXMetagenomi$52.29M1.08N/AN/A$6.28 per share0.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTMDbiote$3.16M$0.616.757.63N/A10.93%-19.44%20.12%8/6/2025 (Estimated)DSGNDesign Therapeutics-$49.59M-$0.99N/AN/AN/AN/A-22.85%-22.02%8/4/2025 (Estimated)INBXInhibrx Biosciences$1.69B$116.750.13N/AN/AN/A-85.12%-58.90%8/12/2025 (Estimated)MGXMetagenomi-$78.06M-$2.11N/AN/AN/A-172.21%-31.21%-22.21%8/13/2025 (Estimated)Latest MGX, BTMD, INBX, and DSGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025DSGNDesign Therapeutics-$0.28-$0.31-$0.03-$0.31N/AN/A5/14/2025Q4 2024INBXInhibrx Biosciences-$2.55-$2.80-$0.25-$2.80N/AN/A5/13/2025Q1 2025MGXMetagenomi-$0.62-$0.68-$0.06-$0.68$8.75 million$4.13 million5/7/2025Q1 2025BTMDbiote$0.06$0.08+$0.02$0.37$47.25 million$48.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTMDbioteN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/AMGXMetagenomiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTMDbioteN/A1.421.14DSGNDesign TherapeuticsN/A28.3728.37INBXInhibrx Biosciences1.045.125.12MGXMetagenomiN/A5.855.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTMDbiote21.68%DSGNDesign Therapeutics56.64%INBXInhibrx Biosciences82.46%MGXMetagenomiN/AInsider OwnershipCompanyInsider OwnershipBTMDbiote24.00%DSGNDesign Therapeutics31.20%INBXInhibrx BiosciencesN/AMGXMetagenomi17.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTMDbiote19454.71 million41.58 millionNot OptionableDSGNDesign Therapeutics4056.77 million39.06 millionOptionableINBXInhibrx Biosciences16614.48 millionN/AOptionableMGXMetagenomi23637.38 million30.73 millionN/AMGX, BTMD, INBX, and DSGN HeadlinesRecent News About These CompaniesMetagenomi, Inc. (NASDAQ:MGX) Shares Sold by Millennium Management LLCJune 15, 2025 | marketbeat.comInsider Selling: Metagenomi, Inc. (NASDAQ:MGX) CEO Sells 10,785 Shares of StockJune 10, 2025 | insidertrades.comMetagenomi, Inc. (NASDAQ:MGX) CEO Sells $18,873.75 in StockJune 9, 2025 | marketbeat.comMetagenomi, Inc. (NASDAQ:MGX) Short Interest Down 18.9% in MayJune 3, 2025 | marketbeat.comCitadel Advisors LLC Decreases Position in Metagenomi, Inc. (NASDAQ:MGX)June 2, 2025 | marketbeat.comMetagenomi, Inc. (NASDAQ:MGX) Analysts Are Cutting Their Estimates: Here's What You Need To KnowMay 16, 2025 | finance.yahoo.com2MGX : Demystifying Metagenomi: Insights From 4 Analyst ReviewsMay 15, 2025 | benzinga.comMetagenomi Reports Promising Hemophilia A Study ResultsMay 14, 2025 | tipranks.comMetagenomi, Inc.: Metagenomi Reports Business Updates and First Quarter 2025 Financial ResultsMay 14, 2025 | finanznachrichten.deMetagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025May 14, 2025 | globenewswire.comMetagenomi (MGX) Reports Q1 Loss, Misses Revenue EstimatesMay 13, 2025 | zacks.comMetagenomi Reports Business Updates and First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comMetagenomi to Present at Upcoming Scientific MeetingsMay 2, 2025 | globenewswire.comMetagenomi Leads The Charge With These 3 Penny StocksApril 10, 2025 | uk.finance.yahoo.comMetagenomi price target lowered to $7 from $14 at H.C. WainwrightApril 4, 2025 | markets.businessinsider.comMetagenomi, Inc. Common Stock (MGX) Latest After Hours TradesMarch 31, 2025 | nasdaq.comBiotech stocks slide as Marks resignation seen being negative for sectorMarch 31, 2025 | markets.businessinsider.comBullish: Analysts Just Made A Significant Upgrade To Their Metagenomi, Inc. (NASDAQ:MGX) ForecastsMarch 27, 2025 | uk.finance.yahoo.comMetagenomi, Inc.: Metagenomi Reports Business Updates and Full Year 2024 Financial ResultsMarch 19, 2025 | finanznachrichten.deMetagenomi Faces Legal Battle Over Alleged Misleading Statements in Moderna CollaborationMarch 19, 2025 | tipranks.comMetagenomi, Inc. Reports 2024 Financial Results and Pipeline ProgressMarch 18, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMGX, BTMD, INBX, and DSGN Company Descriptionsbiote NASDAQ:BTMD$4.12 +0.10 (+2.49%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$4.12 +0.00 (+0.12%) As of 07/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Design Therapeutics NASDAQ:DSGN$3.52 +0.15 (+4.45%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$3.52 0.00 (0.00%) As of 07/1/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Inhibrx Biosciences NASDAQ:INBX$14.67 +0.40 (+2.80%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$14.72 +0.05 (+0.37%) As of 07/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Metagenomi NASDAQ:MGX$1.52 +0.04 (+2.36%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$1.53 +0.02 (+0.99%) As of 07/1/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
